<DOC>
	<DOCNO>NCT00287911</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , topotecan cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high energy x-ray kill tumor cell . Internal radiation use radioactive material place directly near tumor kill tumor cell . Topotecan cisplatin may make tumor cell sensitive radiation therapy . Giving topotecan cisplatin together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose topotecan give together cisplatin radiation therapy treat patient advanced cervical cancer .</brief_summary>
	<brief_title>Topotecan , Cisplatin , Radiation Therapy Treating Patients With Advanced Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose topotecan administer cisplatin patient advanced cervical cancer . - Identify unique toxicity associate administer radiotherapy along adjuvant cisplatin topotecan patient cervical cancer . - Determine feasibility administer continuous infusion topotecan chemotherapy together radiation therapy . - Assess quality life patient treat regimen . OUTLINE : This dose-escalation study topotecan . Patients undergo radiotherapy daily day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36 . Some patient may also undergo brachytherapy . Patients also receive cisplatin intravenously ( IV ) 1 hour day 1 , 8 , 15 , 22 , 29 , 36 topotecan IV continuously day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36 . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Quality life assess baseline 4 14 week completion study treatment . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histologically confirm cervical carcinoma Deemed curable surgery radiotherapy alone The following stage eligible : Stage IIB Stage IIIA IIIB Stage IVA Stage IB IIA ≥ 1 follow risk factor : Primary tumor ≥ 6 cm Positive pelvic and/or paraaortic lymph node ( resect unresected ) Positive surgical margin Depth invasion &gt; 50 % positive capillarylymphatic space involvement The follow histologic subtypes eligible : Squamous Adenosquamous Adenocarcinoma No recurrent cervical cancer Gynecologic Oncology Group ( GOG ) performance status 0 , 1 , 2 White blood cell ( WBC ) ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Granulocyte count ≥ 1,500/mm^3 Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 1.5 time institutional normal Serum glutamic oxaloacetic transaminase ( SGOT ) alkaline phosphatase ≤ 3 time institutional normal No prior concurrent malignancy skin ( exclude melanoma ) No septicemia , severe infection , gastrointestinal bleeding , intestinal obstruction No anatomic abnormality ( e.g. , pelvic kidney renal transplant ) require modification radiation field Fertile patient must use effective contraception Negative pregnancy test Patients evidence abnormal cardiac conduction ( e.g. , bundle branch block , heart block ) eligible disease stable past 6 month Recovered recent surgery Prior pelvic radiation Pregnant nursing History thrombus History unstable angina myocardial infarction within past 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
</DOC>